RANIBIZUMAB

Course overview

RANIBIZUMAB IS A MEDICATION USED IN THE MANAGEMENT AND TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, MACULAR EDEMA FOLLOWING RETINAL VEIN OCCLUSION, DIABETIC MACULAR EDEMA, MYOPIC CHOROIDAL NEOVASCULARIZATION, AND DIABETIC RETINOPATHY. IT IS IN THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF-A) INHIBITORS CLASS OF MEDICATIONS. THIS ACTIVITY DESCRIBES THE INDICATIONS, ACTION, AND CONTRAINDICATIONS FOR RANIBIZUMAB AS A VALUABLE AGENT IN THE TREATMENT OF OCULAR DISEASES WITH ABNORMAL ANGIOGENESIS. THIS ACTIVITY WILL ALSO HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS (E.G., INDICATIONS, DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, MONITORING, RELEVANT INTERACTIONS) PERTINENT FOR MEMBERS OF THE INTERPROFESSIONAL PROFESSIONAL TEAM IN THE MANAGEMENT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, MACULAR EDEMA, DIABETIC RETINOPATHY, AND RELATED CONDITIONS.